Qbd Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 09-12-2024
- Paid Up Capital ₹ 1.49 Cr
as on 09-12-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 26.79%
(FY 2020)
- Profit 96.92%
(FY 2020)
- Ebitda 88.03%
(FY 2020)
- Net Worth -4.53%
(FY 2020)
- Total Assets 46.64%
(FY 2020)
About Qbd Biosciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.49 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mitul Agarwal and Supriya Agarwal serve as directors at the Company.
- CIN/LLPIN
U74999HR2017PTC069875
- Company No.
069875
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Rohtak, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Qbd Biosciences Private Limited offer?
Qbd Biosciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Protein Powder, Anti Infective Drugs & Medicines, Antiviral Drugs, Dentist Tools, Equipment & Supplies, Dental Accessories, Brain & Nervous System Drugs, Immunomodulator Drugs, Surgical & ICU Equipments, Pulse Oximeter, Glucometer & POCT Devices.
Who are the key members and board of directors at Qbd Biosciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mitul Agarwal  | Director | 02-Sep-2021 | Current |
| Supriya Agarwal | Director | 15-Nov-2022 | Current |
Financial Performance and Corporate Structure Insights of Qbd Biosciences.
Qbd Biosciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 26.79% increase. The company also saw a substantial improvement in profitability, with a 96.92% increase in profit. The company's net worth dipped by a decrease of 4.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Qbd Biosciences?
In 2020, Qbd Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anabolic Health Solutions LlpActive 13 years 6 monthsMitul Agarwal and Supriya Agarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Qbd Biosciences?
Unlock and access historical data on people associated with Qbd Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Qbd Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Qbd Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
